Anteris gets German regulatory clearance for DurAVR heart valve trial

AVR•2026-10-20

Anteris Technologies received German regulatory clearance for its PARADIGM pivotal trial of the DurAVR transcatheter heart valve, enabling patient recruitment at German centers.

1. Trial recruitment enabled

Anteris Technologies received German regulatory clearance for its PARADIGM pivotal trial of the DurAVR transcatheter heart valve. The clearance enables patient recruitment at German centers for the trial, which targets severe calcific aortic stenosis.

Anteris gets German regulatory clearance for DurAVR heart valve trial

1. Trial recruitment enabled

Related News

Vivos Therapeutics closes acquisition of SOD Sciences stake and 50% interest in pseudohypoxia test

Musk, Anthropic outline dueling approaches to AI-era philanthropy

Securities class action filed against Curanex Pharmaceuticals and underwriters on July 23, 2026

Bitdeer announces September 2026 production and operations update

Asian shares tumble, oil rises as markets await AI sector results